Macrolide antibiotics and survival in patients with acute lung injury

Chest

Volumn 141, Issue 5, 2012, Pages 1153-1159

  Walkey, Allan J ^a   Wiener, Renda S ^a,b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; ERYTHROMYCIN; LISOFYLLINE; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); NONPULMONARY SEPSIS; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; TIDAL VOLUME; TREATMENT DURATION;

EID: 84860581686     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-1908     Document Type: Article

References (33)

1. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685-1693. (Pubitemid 41464707)
2. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301- 1308.
3. The ARDS Network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2000;283(15):1995-2002.
4. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ. 2007;334(7597):779.
5. Steinberg KP, Hudson LD, Goodman RB, et al National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671-1684.
6. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med. 2006;173(3):281-287. (Pubitemid 43209082)
7. Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med. 2008;178(6):618-623.
8. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med. 2002;30(1):1-6.
9. López-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol. 2008;8(3):286-291.
10. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics-part 1: biological mechanisms. Respiration. 2011;81(1):67-74.
11. Wunderink RG. Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med. 2009; 30 (2): 146- 153.
12. Akira M, Higashihara T, Sakatani M, Hara H. Diffuse panbronchiolitis: follow-up CT examination. Radiology. 1993;189(2):559-562. (Pubitemid 23321444)
13. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57(3):212-216. (Pubitemid 34214405)
14. Sato K, Suga M, Akaike T, et al. Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. Am J Respir Crit Care Med. 1998;157(3 Pt 1):853-857.
15. Kawashima M, Yatsunami J, Fukuno Y, Nagata M, Tominaga M, Hayashi S. Inhibitory effects of 14-membered ring macrolide antibiotics on bleomycin-induced acute lung injury. Lung.2002;180(2):73-89. (Pubitemid 35477917)
16. Leiva M, Ruiz-Bravo A, Jimenez-Valera M. Effects of telithromycin in in vitro and in vivo models of lipopolysaccharide-induced airway inflammation. Chest. 2008;134(1):20-29. (Pubitemid 352008759)
17. Tamaoki J, Kondo M, Kohri K, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol. 1999;163(5):2909-2915. (Pubitemid 29399222)
18. Tamaoki J, Takeyama K, Yamawaki I, Kondo M, Konno K. Lipopolysaccharide- induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am J Physiol.1997;272(1 Pt 1):L15-L19.
19. Tamaoki J, Tagaya E, Yamawaki I, Sakai N, Nagai A, Konno K. Effect of erythromycin on endotoxin-induced microvascular leakage in the rat trachea and lungs. Am J Respir Crit Care Med. 1995;151(5):1582-1588.
20. Azuma A, Furuta T, Enomoto T, et al. Preventive effect of erythromycin on experimental bleomycin-induced acute lung injury in rats. Thorax. 1998;53(3):186-189. (Pubitemid 28172369)
21. Bernard GR, Artigas A, Brigham KL, et al The Consensus Committee. Report of the American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. Intensive Care Med.1994;20(3):225-232. (Pubitemid 24088590)
22. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993; 270 (24): 2957-2963. (Pubitemid 24000804)
23. Bernard GR. The Brussels Score. Sepsis. 1997;1(1):43-44.
24. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 2003; 168(1):49-53. (Pubitemid 37046632)
25. Schoenfeld DA, Bernard GR; ARDS Network. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002;30(8):1772-1777. (Pubitemid 34879589)
26. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
27. Zhehui Luo, Gardiner JC, Bradley CJ. Applying propensity score methods in medical research: pitfalls and prospects. Med Care Res Rev. 2010;67(5):528-554.
28. Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004;125(suppl 2):41S-50S; quiz 51S.
29. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis. 2008; 46(8):1157-1164. (Pubitemid 351589897)
30. Ichiyama T, Nishikawa M, Yoshitomi T, et al. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother. 2001;45(1):44-47. (Pubitemid 32039091)
31. Yamasawa H, Oshikawa K, Ohno S, Sugiyama Y. Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. Am J Respir Cell Mol Biol. 2004;30(4):569-575. (Pubitemid 38457190)
32. Labro MT, el Benna J, Babin-Chevaye C. Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother. 1989;24(4):561-572. (Pubitemid 19262784)
33. Howard AE, Courtney-Shapiro C, Kelso LA, Goltz M, Morris PE. Comparison of 3 methods of detecting acute respiratory distress syndrome: clinical screening, chart review, and diagnostic coding. Am J Crit Care. 2004;13(1):59-64. (Pubitemid 39456768)